clinical trial · NCT07418749
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 398
Recurrent Cervical CancerMetastatic Cervical CancerSHR-A2102 for InjectionPemetrexed Disodium for InjectionGemcitabine Hydrochloride for InjectionTopotecan Hydrochloride for InjectionPaclitaxel for Injection (Albumin bound)
brief summary
The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
started
Mar 30, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2028
last updated
Apr 6, 2026
official title
An Open-label, Randomized, Controlled, Multicenter, Phase III Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol